June 19, 2013 | Vol. 10 No. 120
“Pay-for-delay” deals between brand drugmakers and their generic competitors can sometimes violate antitrust law, the Supreme Court ruled Monday, issuing a tempered decision that will make it easier for legal challenges to be brought by critics of the practice.
The European Medicines Agency May 8 published recommendations for drugmakers on the use of phthalates and parabens, urging consideration of patient populations.
Drugmakers’ shortage-prevention programs aren’t catching quality deviations as designed, according to a new survey that paints a stark picture of shortage prevalence.
The Trans-Pacific Partnership is just another corporate power grab, says Margaret Flowers, a doctor who served as a Congressional fellow for Physicians for a National Health Program.
India’s Supreme Court agreed last week to hear a case against a license granted to Ranbaxy as well as allegations that the company distributed substandard drugs.
Last week, hundreds of drugs being sold at the Hmongtown market in St. Paul, Minn., were confiscated after customers complained of illnesses believed to be tied to those drugs.
India and Argentina have agreed to strengthen trade between the two countries in multiple areas, including in the pharmaceutical arena.
Everything you ever wanted to know about Enbrel and the ways in which drugs that treat chronic inflammatory diseases are changing the pharmaceutical market.
Government fuel price hikes are likely to increase pharmaceutical drug prices in Indonesia.
ePublishing :: CMS, Hosting & Web Development | © Copyright by FDAnewsAll rights reserved. Do not duplicate or redistribute in any form.